Sector Expert: Pooya Hemami

Edison Investment Research

Image: Pooya Hemami

Pooya Hemami is a licensed optometrist with more than eight years of experience in life sciences equity research. Prior to joining Edison Investment Research, he covered the Canadian healthcare sector as a research analyst at Desjardins Capital Markets. He holds a doctor of optometry degree from the University of Montreal, and a master's degree in business administration (finance concentration) from McGill University. He received his CFA charter in 2011.



Recent Quotes

"BCLI is planning a Phase 2 NurOwn study in Israel, to start by 2015E."

— Pooya Hemami, Edison Investment Research (9/23/15)
more >

"If CANF's product can show decent efficacy, while maintaining the reasonable safety profile shown thus far, it is positioned to do well."

The Life Sciences Report Interview with Pooya Hemami (10/15/14)
more >

"Our risk-adjusted NPV for BLU continues to reflect upside."

— Pooya Hemami, Edison Investment Research (10/6/14)
more >

"BLU's investment case includes premium pricing potential for Kiacta."

— Pooya Hemami, Edison Investment Research (6/30/14)
more >

"BLU is fully funded beyond the Kiacta study results."

— Pooya Hemami, Edison Investment Research (5/12/14)
more >

"BLU's reduction in the time to Kiacta phase 3 study data is positive."

— Pooya Hemami, Edison Investment Research (1/7/14)
more >

"BLU divested its noncore assets to focus on Kiacta and Shigamabs."

— Pooya Hemami, Edison Investment Research (11/8/13)
more >

"Following the Zenith spinout, RVX retains rights to lead candidate RVX-208."

— Pooya Hemami, Edison Investment Research (6/14/13)
more >



Due to permission requirements, not all quotes are shown.